2022 China Biopharmaceutical Future Development Summit
Theme: Exploring the Journey to Innovation and Commercialization of Biopharmaceuticals
December 1 – 2, 2022
December 1 – 2, 2022
Organizers: Merck China, BioPhorum, Ouryao
Register to receive your link to attend as a virtual participant and hear about China’s bright biopharmaceutical future.
The link to join will be sent at least 24 hours prior to the conference, so fill in your details now to secure your place.
Dec 1, Day 1:Biopharmaceutical industrialization development and application of innovative technology
Time | Theme | Featured Speaker | Affiliation and Title |
---|---|---|---|
09:30-09:35 | Opening Speech | Mr. Michael Ju | Head of Merck Life Science BioProcessing Solution China |
09:35-09:40 | Opening Speech | Dr. Tim Hawkins | CEO,BioPhorum |
09:40-09:45 | Opening Speech | Mr. Zhang Jinwei | Founder, Ouryao |
09:45-10:15 | Synthetic Biotechnology Boosts the Innovation and Development of Biological Drug Manufacturing | Academician, Zheng Yuguo | Director of Academic Committee, Zhejiang University of Technology |
10:15-10:45 | Exploration on regulatory scientific research to promote the high-quality development of the biomedical industry | Dr Cao Meng | Deputy Director, Innovation and Regulatory Science Development Dept, Shanghai Center for Drug Evaluation and Inspection |
10:45-11:15 | How industry have adapted to changes in China CMC Regulatory | Dr. Mei Cai | PAS China Team, BioPhorum & Director in the Regulatory Affairs, CMC (RA CMC), AbbVie, Inc. |
11:15-11:30 | Tea break | ||
11:30-12:15 | Round-table discussion: How Innovative Biological Drugs Enterprises Leap Forward under challenges Dr Yang Zhe, National Sales Director of Merck Life Science BioProcessing Solution China | TBD | Chief Evaluator,Shanghai Center for Drug Evaluation and Inspection |
Ms. Liu Ding | Vice General Manager, Qilu Pharmaceutical Biological | ||
Dr Zhou Weichang | President & Chief Technology Officer, Wuxi Biologics | ||
Dr Zhou Kaisong | Senior Executive Vice President,Innovent Biologics (Suzhou) Co., Ltd. | ||
Dr Shi Qiuming | Head of Customer Application, Merck Life Science BioProcessing Solution China | ||
12:15-13:30 | Luncheon | ||
13:30-13:45 | Merck China- GenScript Biotech, Strategic Partnership Signing Ceremony | ||
13:45-14:15 | Future Development Trend of Bioprocess Technology | Dr Zhou Weichang | President & Chief Technology Officer, Wuxi Biologics |
14:15-14:45 | Early-mover presence: development journey for Chinese biopharmaceutical companies | Ms. Liu Ding | Vice General Manager, Qilu Pharmaceutical Biological |
14:45-15:15 | Challenges and opportunities faced by biopharmaceutical industrialization in China | Dr Zhou Kaisong | SVP, Innoventbio (Suzhou) Co.,Ltd |
15:15-15:30 | Tea break | ||
15:30-16:00 | Focus on local demand, accelerate Launch of Innovative Bio-drugs | Dr Shi Qiuming | Director of Technical Application, BioProcessing, China, Life Science business of Merck |
16:00-16:30 | The internationalization of biological medicine with Chinese characteristics | Dr Li Dong | General Manager, Shanghai R & D Center, Rongchang Pharmaceuticals (Yantai) Co.,Ltd |
16:30-17:00 | Masterclass in embracing innovation in biomanufacturing | Mr. Guido Kremer-van der Kamp | Senior Consultant, Global BioPharm CoE, Merck KGaA (Life Science) |
Dec 2,Day 2:Biological Drug (Antibody) Process Development And Quality Control Strategy
Time | Theme | Featured Speaker | Affiliation and Title |
---|---|---|---|
09:30-10:00 | Continuous production of biological products from a regulatory perspective | Dr. Yang | Drug Inspector |
10:00-10:30 | Continuous Manufacturing - Alignment with Quality Risk Management (QRM) Principles | Ms Ushma Mehta | Senior Legal Counsel, Merck Global |
10:30-10:45 | Tea break | ||
10:45-11:15 | Developing Industry Consensus to De-Risk and Simplify the Adoption of Continuous Biomanufacturing | Dr. Charles Heise | Senior Staff Scientist, FUJIFILM Diosynth Biotechnologies |
11:15-11:45 | ADC Drug Process Development and Manufacturing Challenges And Strategies | Dr Luo Jianjun | VP & chief executive for Manufacturing, Wuxi Biologics Technology |
11:45-12:15 | Explore Commercial Production of Novel Dual-Specific Antibody Drugs | Mr. Jiang Jing | Head of Group Production, Akesobio, Inc |
12:15-13:30 | Luncheon | ||
13:30-14:00 | Key points for application of continuous antibody processes in production | Dr Zhang Xichen | General Manager, Hangzhou Yi 'an Ji Shi Biological Pharmaceutical Co., LTD |
14:00-14:30 | Risk Assessment for Single-Use Continuous Biomanufacturing Processes: the Upstream Case | Mr Wang Bin | Head of Scientific & Technological Solutions, Merck Life Science BioProcessing Solution China |
14:30-15:00 | Upstream perfusion process development strategy and case sharing | Dr Ji Yu | Director of Biomedicine Process Development, Beigene (Suzhou ) Biological Technology Co.,Ltd |
15:00-15:15 | Tea break | ||
15:15-15:45 | Development strategy of efficient perfusion culture media | Ms San Dan | Director of Upstream R & D, Merck Life Science BioProcessing Solution China |
15:45-16:15 | Downstream process enhancement and cost considerations | Ms Liao Siyi | Head of MSAT downstream purification and technical operations, Merck Life Science BioProcessing Solution China |
16:15-16:45 | Reflection and practice of digital transformation of biopharmaceutical production | Mr Zhang Hong | Senior Director of Intelligent Information Dept, Shanghai Junshi Biosciences Co., Ltd |